Moldova Pharmaceuticals and Healthcare Report Q3 2013:Life Sciences Market Research Reports

Life Sciences Market Research Reports

Moldova Pharmaceuticals and Healthcare Report Q3 2013 Jul 24th 2013, 00:00, by jayshree BMI View: Moldova will not witness a sudden influx of multinational drugmakers. Combined with limited public sector healthcare resources, its low per capita incomes and thus pharmaceutical spending will continue to provide few opportunities for research-based pharmaceutical manufacturers, although we note that Moldova remains committed to healthcare modernisation and European integration. Headline Expenditure Projections ? Pharmaceuticals: MDL2.59bn (US$214mn) in 2012 to MDL2.74bn (US$215mn) in 2013; +5.9% in local currency terms and +0.5% in US dollar terms. Forecast unchanged from Q213. ? Healthcare: MDL9.62bn (US$795mn) in 2012 to MDL10.36bn (US$830mn) in 2013; +7.7% in local currency terms and +2.3% in US … Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=108337. Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/moldova-pharmaceuticals-and-healthcare-report-q3-2013-market-report.html.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions